Zavegepant for the acute treatment of migraine: look before leaping

The armamentarium of acute medications for migraine is set to expand further with the results of a phase III trial, in which intranasal administration of zavegepant was superior to placebo in treating a single migraine attack. The therapeutic benefits were modest, however, and so more work is needed to address unmet treatment needs.